Company Description
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.
It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.
It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria.
In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors.
It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions.
The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019.
Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Steven Adam Lisi |
Contact Details
Address: 900 Stewart Avenue, Suite 301 Garden City, New York 11530 United States | |
| Phone | 516-665-8200 |
| Website | beyondair.net |
Stock Details
| Ticker Symbol | XAIR |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001641631 |
| CUSIP Number | 08862L103 |
| ISIN Number | US08862L1035 |
| Employer ID | 47-3812456 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Steven Adam Lisi | Chief Executive Officer and Chairman of the Board |
| Amir Avniel | Co-Founder, President, Chief Business Officer and Director |
| Michael A. Gaul | Chief Operating Officer |
| Douglas Quinton Larson | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Edward Barger | Head of Investor Relations |
| Kori-Ann Taylor | Head of Marketing |
| Dr. Andrew R. Colin M.D. | Senior Medical Director Global Clinical Leadership and Member of Scientific Advisory Board |
| Dr. Jeff Myers M.D., Ph.D. | Chief Medical Officer |
| Adam Newman | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 9, 2024 | D | Notice of Exempt Offering of Securities |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 10-K | Annual Report |
| Jun 18, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 424B5 | Filing |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 1, 2024 | 424B5 | Filing |
| Mar 1, 2024 | 8-K | Current Report |